Industry·7:31 AM MT
A new meta-analysis compared weight loss outcomes for three GLP-1 receptor agonists: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated clinical efficacy data across the three drug classes to determine comparative effectiveness for weight management. The findings provide evidence that could inform prior authorization criteria, formulary placement, and medical policy for obesity treatment in Medicaid managed care plans. Many state Medicaid programs have restricted or excluded coverage of anti-obesity medications due to cost, making comparative effectiveness data particularly relevant for coverage and utilization management decisions.
Why it matters for managed careComparative effectiveness data on GLP-1 medications directly impacts formulary design, prior authorization protocols, and medical policy for obesity treatment coverage in Medicaid managed care plans facing mounting utilization and cost pressure.
Industry·1:30 PM MT
An FDA advisory panel recommended approval of Moderna's mFlusiva, the first mRNA-based influenza vaccine, for adults ages 50-64 and those 65 and older under specific conditions. In late-stage trials, the vaccine demonstrated 27% greater effectiveness compared to standard flu shots. The panel's recommendation followed a June 18 meeting where FDA officials reviewed the clinical data. Final FDA approval would mark the first mRNA flu vaccine on the market, potentially expanding vaccine options for Medicaid managed care plans covering adult populations.
Why it matters for managed careA new mRNA flu vaccine with higher efficacy could affect MCO vaccine procurement strategies, pharmacy benefit management, and HEDIS flu vaccination rates for Medicare-Medicaid dual eligibles and adult Medicaid populations.